Crucially, recent evidence has demonstrated that intestinal microbiota–driven inflammatory and oxidative pathways can modulate ABC efflux transporters, including Mrp2, primarily through regulatory mechanisms dependent on FXR and Nrf2, as described in models of metabolic dysfunction-associated steatohepatitis and toxin-induced liver injury [29,30,31]. The gene discussed is ABCC2; the disease is injury.